Where is Abbott Laboratories's capital expenditure disclosed?
The figure, the filing and period it comes from, and the reported definition.
The answer
$2.17B
Capital expenditure, fiscal year ending Dec 31, 2025
Document: 10-K filed 2026-02-20 (accession 0001628280-26-010185)
Reported as XBRL element PaymentsToAcquirePropertyPlantAndEquipment (Payments to Acquire Property, Plant, and Equipment).
Definition: The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Calculation: none — the value is reported directly.
Source register
| Period end | Value | Form | Filed | Accession |
|---|---|---|---|---|
| Dec 31, 2018 | $1.39B | 10-K | 2021-02-19 | 0001104659-21-025751 |
| Dec 31, 2019 | $1.64B | 10-K | 2022-02-18 | 0001104659-22-025141 |
| Dec 31, 2020 | $2.18B | 10-K | 2023-02-17 | 0001628280-23-004026 |
| Dec 31, 2021 | $1.89B | 10-K | 2024-02-16 | 0001628280-24-005348 |
| Dec 31, 2022 | $1.78B | 10-K | 2025-02-21 | 0001628280-25-007110 |
| Dec 31, 2023 | $2.20B | 10-K | 2026-02-20 | 0001628280-26-010185 |
| Dec 31, 2024 | $2.21B | 10-K | 2026-02-20 | 0001628280-26-010185 |
| Dec 31, 2025 | $2.17B | 10-K | 2026-02-20 | 0001628280-26-010185 |